11.0% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Tue Apr 08, 11:18AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 11.00% as of today's recent price of $9.79.
CardioNet Shares Up 17.8% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Tue Apr 01, 9:59AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 17.80% as of today's recent price of $10.39.
BioTelemetry, Inc. Announces the Acquisition of the Cardiac Patient Services Business of Biomedical Systems, Corp.
GlobeNewswire - Thu Mar 20, 7:14AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that it has entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems, Corp. ("BMS"
CardioNet Up 15.5% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 5:33PM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 15.53% as of today's recent price of $10.19.
CardioNet Earnings In Retrospect: Up 4.9% in the Last 19 Days (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 7:10AM CDT
Two weeks ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. CardioNet actually reported earnings of $0.05 per share on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.33, representing a gain of 4.9% in the past 19 days.
BioTelemetry (BEAT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:33AM CDT
BioTelemetry belongs to the Medical Services industry, will be a decent pick, as the company witnessed solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
CardioNet Earnings Review: 12 Days after Announcement Shares Up 10.7% (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 7:53AM CDT
A week ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. The company actually reported EPS of $0.05 on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.90, representing a gain of 10.7% in the past 12 days.
Why BioTelemetry (BEAT) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:00AM CST
BioTelemetry has decent short-term momentum and solid activity on the earnings estimate revision front
25.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 03, 9:49AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 4 weeks, CardioNet has returned 25.40% as of today's recent price of $11.06.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Why BioTelemetry (BEAT) Is Spiking Today
at The Street - Thu Feb 27, 12:52PM CST
BioTelemetry (BEAT) rises after the company, which provides products and services to healthcare professionals to help diagnose and monitor patients, reported fourth-quarter earnings that surpassed analysts' expectations. BioTelemetry reported fourth...
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
BioTelemetry, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year-ended December 31, 2013.
Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.
BioTelemetry (BEAT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:51AM CST
BioTelemetry (BEAT) Shares March Higher, Can It Continue?
Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks
Healthways Sees 4Q Loss on Lower Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:07PM CST
Healthways failed to meet its own revenue expectations of 171 to $181 million for the fourth quarter and $665-$675 million for the full year